RT Journal Article
SR Electronic
T1 Combining two large clinical cohorts (AIBL and ADNI) to identify multiple lipid metabolic pathways in prevalent and incident Alzheimer’s disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.26.20114215
DO 10.1101/2020.05.26.20114215
A1 Huynh, Kevin
A1 Lim, Wei Ling Florence
A1 Giles, Corey
A1 Jayawardana, Kaushala S
A1 Salim, Agus
A1 Mellett, Natalie A
A1 Smith, Alex
A1 Olshansky, Gavriel
A1 Drew, Brian G
A1 Chatterjee, Pratishtha
A1 Martins, Ian
A1 Laws, Simon M
A1 Bush, Ashley I
A1 Rowe, Christopher C
A1 Villemagne, Victor L
A1 Ames, David
A1 Masters, Colin L
A1 Arnold, Matthias
A1 Nho, Kwangsik
A1 Saykin, Andrew J
A1 Baillie, Rebecca
A1 Han, Xianlin
A1 Kaddurah-Daouk, Rima
A1 Martins, Ralph N
A1 Meikle, Peter J
YR 2020
UL http://medrxiv.org/content/early/2020/05/28/2020.05.26.20114215.abstract
AB Changes to lipid metabolism are tightly associated with the onset and pathology of Alzheimer’s disease (AD). Lipids are complex molecules comprising of many isomeric and isobaric species, necessitating detailed analysis to enable interpretation of biological significance. Our expanded targeted lipidomics platform (569 lipid species across 32 lipid (sub)classes) allows for detailed isomeric and isobaric lipid separation. We applied the methodology to examine plasma samples from the Australian Imaging, Biomarkers and Lifestyle flagship study of aging (AIBL, n = 1112) and serum from the Alzheimer’s Disease Neuroimaging Initiative (ADNI, n = 800) studies. Cross sectional analysis using both cohorts identified concordant unique peripheral signatures associated with AD. Specific pathways include; sphingolipids, including GM3 gangliosides, where their acyl composition drove the major associations, and lipids previously associated with dysfunctional lipid metabolism in cardiometabolic disease including the phosphatidylethanolamine and triglyceride classes. Infomation derived from improved isomeric seperation highlighted pathway-specific changes with ether lipids including plasmalogens implicating perixosmal dysfunction in disease pathology. Longitudinal analysis revealed similar lipid signitures in both AIBL and ADNI cohorts with future disease onset. We utilised the two independent studies to train and validate multivariate lipid models that significantly improved disease classification and prediction. Together our results provide a holistic view of the lipidome and its relationship with AD using a comprehensive lipidomics approach, providing targets for further mechanistic investigation.Competing Interest StatementA provisional patent has been filed using the AIBL data. Application number: App Number 2018901220; DEMENTIA RISK ANALYSIS; Baker Heart and Diabetes Institute, Edith Cowan UniversityFunding StatementFunding for the AIBL study was provided in part by the study partners [Commonwealth Scientific Industrial and research Organization (CSIRO), Edith Cowan University (ECU), Mental Health Research institute (MHRI), National Ageing Research Institute (NARI), Austin Health, CogState Ltd.]. The AIBL study has also received support from the National Health and Medical Research Council (NHMRC) and the Dementia Collaborative Research Centres program (DCRC2), as well as funding from the Science and Industry Endowment Fund (SIEF) and the Cooperative Research Centre (CRC) for Mental Health funded through the CRC Program (Grant ID:20100104), an Australian Government Initiative. The authors thank the AIBL study participants for their contribution to the study. K.H was supported by a Dementia Australia Research Foundation Scholarship. PJM is supported by a Senior Research Fellowship from the National Health and Medical Research Council of Australia. Support for the metabolomics sample processing, assays and analytics reported here was provided by grants from the National Institute on Aging (NIA); NIA supported the Alzheimers Disease Metabolomics Consortium which is a part of NIAs national initiatives AMP-AD and M2OVEAD (R01 AG046171, RF1 AG051550, RF1 AG057452, and 3U01 AG024904-09S4). Additional NIH support from the NIA, NLM and NCI for analysis includes P30 AG10133, R01 AG19771, R01 LM012535, R03 AG054936, R01 AG061788, K01 AG049050 and R01 CA129769. M.A. is supported by National Institute on Aging grants RF1 AG057452, RF1 AG058942, RF1 AG059093, and U01 AG061359. M.A. is also supported by funding from Qatar National Research Fund NPRP8-061-3-011. K.N is supported by NLM R01 LM012535 and NIA R03AG054936.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Alfred Ethics CommitteeAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData to support this finding is available online and upon request. The entire ADNI lipidomic and clinical characteristic data is available online (adni.loni.usc.edu) and the remaining data (ABIL) used in this study is available from both the corresponding authors and online at https://aibl.csiro.au upon reasonable request.